HIV Care in the COVID-19 Era: The Role of the Healthcare Provider as Both Learner and Educator
  • CME
  • CE

Credits Available
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: November 17, 2021 Expiration: November 16, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
José R. Arribas, MD
Princy N. Kumar, MD, FIDSA, MACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Serve as a trusted source of medical information for persons with HIV that reflects the best available data and guideline recommendations, particularly on topics associated with high levels of misinformation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

José R. Arribas, MD

Research Director (HIV and Infectious Diseases)
Hospital La Paz. IdiPAZ.
Madrid, Spain

José R. Arribas, MD, has disclosed that he has received consulting fees from Aelix, Janssen, MSD, Serono, and ViiV; funds for research support from Gilead Sciences and ViiV; and fees for non-CME/CE services from Gilead Sciences.
Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief,
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, MACP, has disclosed that she has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; has received consulting fees from Amgen, GlaxoSmithKline, and Merck and has ownership interests in Gilead Sciences, Johnson & Johnson, Merck and Pfizer.

Staff

Margaret McLaughlin, PhD
Margaret McLaughlin, PhD, has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jessica Adams, PharmD, BCPS, AAHIVP

Scientific Director

Jessica Adams, PharmD, BCPS, AAHIVP, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who care for persons with HIV in the time of COVID-19.

Goal

The goal of this activity is to improve healthcare professionals’ competence in providing optimal HIV care despite the changing impact of COVID-19 on patient management.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-247-H02-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 100% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 17, 2021, through November 16, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

HIV Care in the COVID-19 Era: The Role of the Healthcare Provider as Both Learner and Educator
  • CME
  • CE

Loading...
In this call between colleagues, hear expert faculty discuss what they learned during the COVID-19 pandemic about the critical role of healthcare providers as sources of trusted information for patients and colleagues, particularly related to COVID-19, and how this role requires mechanisms to stay current on the deluge of emerging data and information. You will also learn about important changes made to the new 2021 guidelines on the treatment of sexually transmitted infections.
José R. Arribas, MD
Princy N. Kumar, MD, FIDSA, MACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Released: November 17, 2021 Expiration: November 16, 2022

Related Content

Expert insight on key ART considerations for people with HIV requiring treatment for drug-susceptible tuberculosis (TB), from Clinical Care Options (CCO)

Daria Podlekareva, MD, PhD Released: March 7, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

Prof Gail Matthews, MD, PhD Released: January 25, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients who are coinfected with HBV/HIV and TB/HIV.

Daria Podlekareva, MD, PhD Mark S. Sulkowski, MD Released: December 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings